Dan Hertz is an Associate Professor at the University of Michigan College of Pharmacy. He received his PharmD from Rutgers University and PhD from University of North Carolina under Dr. Howard McLeod. Dr. Hertz’s research focuses on developing individualized treatment strategies for patients with cancer and translating them into clinical practice. He has particular interests in biomarkers of taxane-induced neuropathy and DPYD testing to prevent severe fluoropyrimidine toxicity.